Tags : Newborns

Pfizer Reports Results of Revatio (sildenafil citrate) in P-III Study

Tuba Khan July 1, 2019

Shots: The P-III study involves assessing of Revatio (IV) + inhaled nitric oxide (iNO) vs iNO as monothx. in newborn babies with persistent pulmonary hypertension The P-III study results did […]readmore

Regulatory

Abbott’s Amplatzer Piccolo Occluder Receives FDA Approval, a Medical Device

Vartika Singh January 15, 2019

Shots: The approval is based on ADO II AS study results assessing the Amplatzer Piccolo in 50 patients with PDA older than three days across eight centers in the US, […]readmore

Tags : Newborns

Pfizer Reports Results of Revatio (sildenafil citrate) in P-III Study

Abbott’s Amplatzer Piccolo Occluder Receives FDA Approval, a Medical Device

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Newborns

﻿Pfizer Reports Results of Revatio (sildenafil citrate) in P-III Study

Abbott’s Amplatzer Piccolo Occluder Receives FDA Approval, a Medical Device

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Pfizer Reports Results of Revatio (sildenafil citrate) in P-III Study